Campbell Roxburgh is Professor of Colorectal Surgical Oncology at the University of Glasgow. He trained in Scotland before undertaking a clinical at Memorial Sloan Kettering Cancer Centre. His research interests include clinical and translational rectal cancer research and clinical trials. He has a leading role in several UK colorectal cancer trials and is chief investigator of the recently completed UK phase II PRIME-RT trial evaluating the addition of Durvalumab immunotherapy to extended neoadjuvant strategies in rectal cancer. He co-leads the Dostarlimab immunotherapy arms of FOxTROT colon cancer phase II neoadjuvant trial platform (FT5 and FT6).  His laboratory group focuses on interrogation of serial tumour samples collected in and out of rectal cancer trials. He has a leading role in the rectal cancer workstream in the CRUK-funded CRC STARS consortium. His clinical interests include robotic cancer surgery and organ preservation in rectal cancer.